Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy and tolerability of a combination tablet of candesartan cilexetiland hydrochlorothiazide in insufficiently controlled primary hypertension-comparison with a combination of losartan and hydrochlorothiazide
Autore:
Ohman, KP; Milon, H; Valnes, K;
Indirizzi:
Linkoping Univ Hosp, Fac Hlth Sci, Dept Med & Care, S-58185 Linkoping, Sweden Linkoping Univ Hosp Linkoping Sweden S-58185 , S-58185 Linkoping, Sweden AstraZeneca AB, Molndal, Sweden AstraZeneca AB Molndal SwedenAstraZeneca AB, Molndal, Sweden Hop Croix Rousse, Serv Cardiol, F-69317 Lyon, France Hop Croix Rousse Lyon France F-69317 Serv Cardiol, F-69317 Lyon, France Stovner, Oslo, Norway Stovner Oslo NorwayStovner, Oslo, Norway
Titolo Testata:
BLOOD PRESSURE
fascicolo: 4, volume: 9, anno: 2000,
pagine: 214 - 220
SICI:
0803-7051(2000)9:4<214:EATOAC>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
BLOOD-PRESSURE; MANAGEMENT;
Keywords:
angiotensin II antagonist; candesartan cilexetil; combination; hydrochlorothiazide; hypertension; losartan;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Ohman, KP AstraZeneca R&D Molndal, SE-43183 Molndal, Sweden AstraZeneca R&D Molndal Molndal Sweden SE-43183 olndal, Sweden
Citazione:
K.P. Ohman et al., "Efficacy and tolerability of a combination tablet of candesartan cilexetiland hydrochlorothiazide in insufficiently controlled primary hypertension-comparison with a combination of losartan and hydrochlorothiazide", BLOOD PRESS, 9(4), 2000, pp. 214-220

Abstract

This randomized, double-blind study compared the antihypertensive effect, safety and tolerability of a candesartan cilexetil/hydrochlorothiazide (candesartan/HCT; 16/12.5 mg) combination tablet with that of a losartan/HCT (50/12.5 mg) combination tablet in patients with mild-to-moderate primary hypertension insufficiently controlled on previous monotherapy. Men and women,aged 20-80 years, with a sitting diastolic blood pressure (DBP) greater than or equal to 90 and less than or equal to 110 mmHg and sitting systolic blood pressure (SBP) less than or equal to 200 mmHg during treatment with any kind of antihypertensive monotherapy for at least 4 weeks were randomizedto candesartan/HCT or losartan/HCT once daily for 12 weeks. All BP measurements were performed 24 h after previous dose. Mean values and standard deviations (SD) or confidence intervals (CI) are given. A total of 340 patients were enrolled, of whom 299 (144 women and 155 men, mean age 59.5 [10.5] years) were randomized to candesartan/HCT (n = 151) or losartan/HCT (n = 148). BPs at randomization were 159.5 (15.4)/98.4 (5.8)mmHg and 160.5 (16.1)/98.5 (5.4) mmHg, respectively. There was a greater reduction in BP with candesartan/HCT than with losartan/HCT: DBP -10.4 (-11.8; -8.9) vs -7.8 (-9.3; -6.3) mmHg, difference between treatments -2.6 (-4.7; -0.5)mmHg (p = 0.016); SBP -19.4 (-22.1; -16.7) vs -13.7 (-16.5; -10.9) mmHg, difference betweentreatments -5.7 (-9.6; -1.8)mmHg (p = 0.004). The proportion of patients achieving a DBP less than or equal to 90 mmHg was greater in the candesartan/HCT group: 60.9 (53.1; 68.7) vs 49.3 (41.3; 57.4)% (p = 0.044). There were12 withdrawals in the candesartan/HCT group, of which 8 were due to adverse events, and 17 and 12, respectively in the losartan/HCT group. We conclude that the combination of candesartan and HCT reduces BP effectively and iswell tolerated. BP was normalized in 61% of these patients who had insufficient response to previous monotherapy. The reduction in BP and the proportion of patients with normalized BP were greater with the candesartan/HCT 16/12.5 mg combination than with the losartan/HCT 50/12.5 mg combination.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 19:29:09